Apellis Pharmaceuticals earnings were -$223.7M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest APLS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$92.2M, up 153.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, APLS reported annual earnings of -$197.9M, with -62.6% growth.
Apellis Pharmaceuticals Earnings Reports & History FAQ
What were Apellis Pharmaceuticals's earnings last quarter?
On APLS's earnings call on Invalid Date, Apellis Pharmaceuticals (NASDAQ: APLS) reported Q1 2025 earnings per share (EPS) of -$0.74, up 37.04% year over year. Total APLS earnings for the quarter were -$92.23 million. In the same quarter last year, Apellis Pharmaceuticals's earnings per share (EPS) was -$0.54.
Is Apellis Pharmaceuticals profitable or losing money?
As of the last Apellis Pharmaceuticals earnings report, Apellis Pharmaceuticals is currently losing money. Apellis Pharmaceuticals's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$223.68 million, a 46.39% decrease year over year.
What was APLS's earnings growth in the past year?
As of Apellis Pharmaceuticals's earnings date in Invalid Date, Apellis Pharmaceuticals's earnings has grown year over year. APLS earnings in the past year totalled -$223.68 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.